Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial
Phase III APOLLO trial shows improved event-free survival in high-risk APL patients receiving arsenic trioxide and ATRA, indicating effectiveness over standard chemotherapy.
Key Points
Two-year event-free survival was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm, a significant difference indicating superior efficacy of the combination therapy.
Molecular relapse occurred in 1.5% of ATRA-ATO patients compared to 12.3% in the ATRA-CHT group, suggesting better long-term outcomes for ATRA-ATO.
Patients receiving ATRA-ATO reported lower serious treatment-emergent adverse events (32%) compared to ATRA-CHT patients (68%), highlighting a potential safety benefit.
The APOLLO trial results support arsenic trioxide and ATRA as effective treatments for high-risk acute promyelocytic leukemia, with implications for clinical practice.